Streptococcus pyogenes vaccine candidates do not induce autoimmune responses in a rheumatic heart disease model

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Streptococcus pyogenes infections can lead to severe post-streptococcal sequelae.
• Developing safe and effective vaccines against multiple S. pyogenes strains is crucial.
• Current vaccine candidates require rigorous preclinical safety evaluation.

Purpose of the Study:

• To evaluate the safety of two candidate vaccine antigens, p*17 and K4S2, derived from S. pyogenes.
• To determine if these antigens induce autoimmune complications and inflammatory pathology in a rat model.
• To provide preclinical evidence for the suitability of p*17 and K4S2 in human clinical trials.

Main Methods:

• Utilized a rat autoimmune valvulitis model to mimic cardiac and neurobehavioral pathology.
• Administered vaccine candidate antigens (p*17-DT, K4S2-DT) via subcutaneous and intranasal routes.
• Included positive (recombinant S. pyogenes M5) and negative (PBS) control groups.

Main Results:

• Rats receiving the positive control (rM5) developed significant cardiac and neurological pathologies.
• No cardiac or neurological pathologies were observed in the negative control group (PBS).
• Rats immunized with p*17-DT or K4S2-DT showed no evidence of autoimmune complications or inflammatory pathology.

Conclusions:

• The vaccine candidates p*17 and K4S2 did not induce autoimmune complications or inflammatory pathology in the rat model.
• These findings provide further preclinical evidence supporting the safety of p*17 and K4S2.
• The evaluated antigens are appropriate candidates for further development in human clinical trials for Streptococcus pyogenes infections.